ArticleVaccines2026

A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil

Erfan Pakatchian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.